Clinical Trial Update: The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO [Phase 4]

View source ↗

Summary

The Phase 4 trial assessing intravenous TXA to reduce perioperative blood loss in patients undergoing PAO has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bleeding

Drugs mentioned

• TXA (tranexamic acid)

Snippet

Sponsor: Boston Children's Hospital | Conditions: Bleeding | Phase 4 | Status: WITHDRAWN